Aberrant splicing and production of TSG101 transcript variations have been detected in multiple types of human cancer, including carcinomas of the liver, lung, breast, cervix, and ovary [46]-[50] as well as in soft tissue sarcomas [51], and leukemias [52]. Here, TSG101 is linked to soft tissue sarcoma.